Merck vs Royalty Pharma
Merck (MRK) and Royalty Pharma (RPRX) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $330B
- Last close
- $133.72
- 12 months
- +40.8%
- Market value
- $39.4B
- Last close
- $68.45
- 12 months
- +78.3%
At a glance
- The biggest part of Merck's revenue is Pharmaceutical, 89% of the total in its last annual report.
- By market value, Merck ($329.7B) is about 8.4 times Royalty Pharma ($39.4B).
- Over the last 12 months Merck's share price moved +40.8% and Royalty Pharma's +78.3%; against the S&P 500 that is +35.1 points and +72.6 points.
- In their last fiscal years Merck kept 28.1% of revenue as net income and Royalty Pharma 32.4%.
- In the last 90 days insiders reported 0 open-market purchases at Merck and 0 at Royalty Pharma; members of Congress disclosed 3 trades in Merck and 0 in Royalty Pharma.
- Next results: Merck Feb 2, 2027, Royalty Pharma Feb 9, 2027.
How each one makes money: Merck revenue · Royalty Pharma revenue
Share prices on one chart
Merck and Royalty Pharma, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Merck MRKNYSE · Pharmaceuticals | Royalty Pharma RPRXNASDAQ · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $330B | $39.4B |
| Revenue, last fiscal year | $65B | $2.38B |
| Net income, last fiscal year | $18.3B | $771M |
| Net marginNet income as a share of revenue | 28.1% | 32.4% |
| Free cash flow | $12.4B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Merck against
Common questions
How is Merck different from Royalty Pharma?
Merck (MRK) is in Pharmaceuticals on NYSE, with $65B of revenue in its last fiscal year and a net margin of 28.1%. Royalty Pharma (RPRX) is in Pharmaceutical Preparations on NASDAQ, with $2.38B of revenue in its last fiscal year and a net margin of 32.4%. The biggest part of Merck's revenue is Pharmaceutical, 89% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Merck and Royalty Pharma compare in size?
Merck has the larger market value: Merck $330B and Royalty Pharma $39.4B, at the last close.
Whose share price rose more over the last 12 months, MRK or RPRX?
Over the last 12 months Merck moved +40.8% and Royalty Pharma +78.3%. Past price moves say nothing about the future.
Which has had more insider buying, Merck or Royalty Pharma?
Since 2006, Merck insiders reported 30 open-market purchases against 18 for Royalty Pharma. These are counts of what was filed, not a view on either stock.
Do members of Congress trade MRK or RPRX?
In the last 12 months, members of Congress disclosed 9 trades in Merck (MRK) and 0 in Royalty Pharma (RPRX).
When did insiders last buy MRK and RPRX?
Merck: Feb 7, 2025. Royalty Pharma: Jun 28, 2023.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Merck pageRoyalty Pharma pageRare insider trades this weekAll comparisons
https://oqro.io/compare/mrk-vs-rprx







